RaphaelEricSteinerMD

PubMed

• 2 citations
  Second malignancies in patients with Hodgkin's Lymphoma: Half a century of experience.
  Bouthaina Shbib Dabaja, David Boyce-Fappiano, Wenli Dong, Ethan Damron, Penny Fang
  Clinical and Translational Radiation Oncology. 2022-07-01
• 27 citations
  Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.
  Guangchun Han, Qing Deng, Mario L Marques-Piubelli, Enyu Dai, Minghao Dang
  Blood Cancer Discovery. 2022-09-06
• 142 citations
  Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
  Chelsea C. Pinnix, Jillian R. Gunther, Bouthaina S. Dabaja, Paolo Strati, Penny Fang
  Blood Advances. 2020-07-14

Abstracts/Posters

• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (_65 years) Patients with Mantle Cell Lymphoma (MCL) _ Results from a...
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements o...
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018